Valiant Laboratories Limited has notified the BSE Limited and the National Stock Exchange of India Limited of an upcoming Board of Directors meeting, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 11, 2026, and signed by Company Secretary & Compliance Officer Akshay Gangurde.

Board Meeting Details

The Board meeting has been scheduled to consider and approve the company's audited financial results for the most recently concluded quarter and full fiscal year. The key details of the meeting are outlined below:

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's own Code of Conduct for Prevention of Insider Trading in Securities, Valiant Laboratories had previously communicated the closure of its Trading Window vide a letter dated March 26, 2026. The Trading Window will continue to remain closed until May 16, 2026.

The intimation has also been uploaded on the company's official website at www.valiantlabs.in .

Valiant Laboratories Limited has formally announced the resignation of its Quality Control Manager, Mr. Bhanudas D. Patil, through an official regulatory filing. The resignation was submitted on April 22, 2026, with immediate effect from the closure of business hours on the same date.

Regulatory Compliance and Filing Details

The company has notified both BSE Limited and National Stock Exchange of India Limited about this senior management personnel change, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary & Compliance Officer Akshay Gangurde signed the official communication on April 23, 2026.

Management Transition Details

According to the formal resignation letter, Mr. Bhanudas D. Patil cited personal commitments as the reason for stepping down from his position. The resignation represents a significant change in the company's quality control leadership structure, as the QC Manager role is critical for overseeing quality assurance processes and regulatory compliance activities.

Quality Control Department Impact

In his resignation letter, Mr. Patil expressed gratitude for the opportunity provided to continue contributing to the organization after his retirement. He acknowledged the support and cooperation extended by the management and colleagues during his tenure. The Quality Control Manager position holds significant responsibility within pharmaceutical operations, ensuring product quality standards and regulatory compliance.

The company has completed the necessary relieving formalities as indicated in the official documentation. This management change follows standard corporate governance practices, with proper disclosure to stakeholders and regulatory authorities as required under SEBI guidelines.